CClinicalTrials.gg
CompletedNCT03485482Updated Apr 2, 2018

Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers

A Phase 3 interventional study of Bisoprolol and Ivabradine in Cardiovascular Diseases, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-04-02.

Sponsored by Ain Shams University · Phase 3, Interventional, and Other

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of the study was to investigate the potential interaction between ivabradine and bisoprolol in healthy subjects.

Read the detailed description

The aim of this study is to undergo a pharmacokinetic study to investigate the incidence of potential pharmacokinetic interaction between Ivabradine and Bisoprolol through the Assessment of the drug-drug interactions of Ivabradine and Bisoprolol by determination of pharmacokinetic parameters of both drugs administered alone and in combination. The pharmacokinetic parameters will include; The maximum plasma concentration (Cmax),the time to reach the peak concentration (tmax), area under the concentration-time curve (AUC0-t) and (AUC0-∞) during the treatment periods, the absorption and elimination rate constants (ka and kel), the half-life and mean residence time (MRT).

Study design A comparative randomized open-label three-period crossover study of ivabradine/ bisoprolol in male healthy human volunteers

Methodology

Eighteen healthy volunteer will be recruited in the study and will be divided into three groups each consisting of six volunteers as follows:

Period I:

  • Group A: Six Volunteers will receive single 10 mg oral dose of ivabradin (Procoralan®, Les Laboratoires Servier Industrie-France).
  • Group B: Six Volunteers will receive single oral dose of bisoprolol 5mg (Concor®).
  • Group C: Six Volunteers will receive a single dose of ivabradine 10 mg and bisoprolol 5 mg

Period II:

  • Group A: Six Volunteers will receive a single dose of ivabradine 10 mg and bisoprolol 5 mg
  • Group B: Six Volunteers will receive single 10 mg oral dose of ivabradin.
  • Group C: Six Volunteers will receive single oral dose of bisoprolol 5mg.

Period III:

  • Group A: Six Volunteers will receive single oral dose of bisoprolol 5mg.
  • Group B: Six Volunteers will receive a single dose of ivabradine 10 mg and bisoprolol 5 mg
  • Group C: Six Volunteers will receive single 10 mg oral dose of ivabradin

All drug administration will be followed by 240 ml of water after at least 10 h fasting prior to administration. The three treatment periods will be separated by a one week washout period. Standardized meals will be served at 2, 5, and 10 h after drug dosing. All subjects should abstain from the consumption of fruit juices during the study period.

Subject Selection Criteria Eighteen adult male volunteers will be enrolled. Subjects should understand the procedures and are willing to participate and give their final written consent prior to the commencement of the study procedures.

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Pharmacokinetic drug interaction
  • ivabtadine
  • bisoprolol
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

Subjects should be healthy adult volunteers with age between (18-45 years) with normal body weight. Subjects should understand the procedures and are willing to participate and gave their final written consent prior to the commencement of the study procedures. The volunteers will be asked to provide a complete medical history, and complete a physical examination, laboratory tests [hematology, clinical chemistry, urinalysis, serology (including hepatitis B surface antigen, anti-hepatitis C virus and antihuman immunodeficiency virus antibody).

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any known enzyme-inducing/inhibiting agents within 30 days prior to the start of the study and throughout the study.
  2. Subjects who have taken any medication less than two weeks of the trials starting date.
  3. Susceptibility to allergic reactions to study drugs.
  4. Any prior surgery of the gastrointestinal tract that may interfere with drug absorption.
  5. Gastrointestinal diseases.
  6. Renal diseases.
  7. Cardiovascular diseases.
  8. Pancreatic disease including diabetes.
  9. Hepatic diseases.
  10. Hematological disease or pulmonary disease
  11. Abnormal laboratory values.
  12. Subjects who have donated blood or who have been involved in multiple dosing study requiring a large volume of blood (more than 500 ml) to be drawn within 6 weeks preceding the start of the study.
04

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Group Ivabradine

    six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose

    Drug: Ivabradine

  • Experimental
    Group Bisoprolol

    six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg

    Drug: Bisoprolol

  • Experimental
    Group combination

    six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg

    Drug: combination of Ivabradine and bisoprolol

Interventions

  • DrugBisoprolol

    bisoprolo 5 mg tablets

    Also known as: Concor

  • DrugIvabradine

    Ivabradine 10 mg tablet

    Also known as: Procorloan

  • Drugcombination of Ivabradine and bisoprolol

    combination of 10 mg ivabradine and 5 mg bisoprolol

    Also known as: concor plus procorolan

05

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters

    AUC0→∞

    Time frame: 48 hours

  2. Pharmacokinetic parameters

    AUC0→t

    Time frame: 48 hours

  3. Bioavailability parameters

    Cmax

    Time frame: 48 hours

  4. Bioavailability parameters

    t max

    Time frame: 48 hours

06

Study locations

1 site
  • Faculty of Pharmacy
    Cairo, Egypt
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03485482
Lead sponsor
Ain Shams University
Responsible party
Sara Mahmoud Shaheen (Associate Professor, Faculty of pharmacy, Ain Shams University, Ain Shams University) — Principal investigator
First posted
Apr 2, 2018
Start date
Mar 1, 2018
Primary completion
Mar 23, 2018
Completion
Mar 23, 2018
Last update
Apr 2, 2018

Study contacts

Sara Shaheen, Ass. Prof
principal investigator · Faculty of pharamacy, Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion